Adaptive Biotechnologies (NASDAQ: ADPT) holder files Form 144 sale

Rhea-AI Filing Summary

Adaptive Biotechnologies security holder files a Form 144 notice to sell common stock. The filing covers a proposed sale of 11,081 shares of common stock through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of $174,636.56 and an approximate sale date of 01/12/2026.

The shares to be sold were acquired through stock option exercises, including 8,581 shares exercised for cash on 01/12/2026 and 2,500 shares previously exercised for cash on 03/14/2025. Over the past three months, the person for whose account the securities are to be sold has already sold common shares, including 162,820 shares on 11/28/2025 for gross proceeds of $3,174,534.10 and 238 shares on 11/17/2025 for $3,343.90, with one entry identified as 10b5-1 sales.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	11081	174636.56	152665188	01/12/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/12/2026	Exercise of Stock Options	Issuer			8581	01/12/2026	Cash
Common	03/14/2025	Previously Exercised Stock Options	Issuer			2500	03/14/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for KYLE J PISKEL 1165 Eastlake Avenue East Seattle WA 98109	Common	11/28/2025	162820	3174534.10
KYLE J PISKEL 1165 Eastlake Avenue East Seattle WA 98109	Common	11/17/2025	238	3343.90

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filing for ADPT disclose?

The Form 144 filing discloses that a holder of Adaptive Biotechnologies (ADPT) common stock plans to sell 11,081 shares, with an aggregate market value of $174,636.56, on NASDAQ through Morgan Stanley Smith Barney LLC.

When and how were the ADPT shares in this Form 144 acquired?

The shares were acquired through stock option exercises, including 8,581 common shares acquired on 01/12/2026 for cash and 2,500 common shares acquired on 03/14/2025 for cash, both from the issuer.

What prior ADPT stock sales are reported in the last three months?

The filing reports past three-month sales including 162,820 common shares sold on 11/28/2025 for gross proceeds of 3,174,534.10 and 238 common shares sold on 11/17/2025 for 3,343.90.

Is a Rule 10b5-1 trading plan referenced in this ADPT Form 144?

Yes. The table of recent activity includes an entry labeled "10b5-1 Sales for KYLE J PISKEL", indicating that at least some of the common share sales were made under a Rule 10b5-1 trading arrangement.

Which broker is handling the planned ADPT share sale in this filing?

The planned sale of 11,081 ADPT common shares is to be executed through Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, 8th Floor, New York, NY 10004.

On which exchange are the ADPT shares in this Form 144 expected to be sold?

The Form 144 states that the common shares covered by the notice are expected to be sold on the NASDAQ securities exchange.